{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:55:16Z","timestamp":1767894916953,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Perceptions and experiences of shared decision\u2010making between patients and physicians in multiple myeloma (MM) care are not fully understood. A survey study was conducted to explore these perspectives in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two anonymous online surveys, one for haematologists and one for MM patients, were developed. Both included related questions on treatment goals, treatment options discussion and the decision\u2010making process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 72 haematologists and 76\u2009MM patients completed the survey, including 23 in first\u2010line treatment, 37 in second\u2010line or later and 16 with no or unknown treatment line. The most common treatment goal for patients (67%) and haematologists (90%) was to prolong survival with a good quality of life. Becoming symptom\u2010free was the second most important treatment goal for patients and haematologists, followed by extending survival over quality of life for patients and quality of life over survival for haematologists. Both groups agreed that minimising hospital visits was the least important treatment goal. While 92% of haematologists reported discussing treatment goals with their patients, 17% of patients reported having this discussion. Discordances between haematologists and patients emerged in perceptions of who made the final treatment decision.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>While general agreement between patients and haematologists on extending survival with good quality of life was found for the main treatment goal, a need to align second treatment goals and improve the shared decision\u2010making was identified. Addressing these differences is important to ensure the selection of the most appropriate treatment for the individual patient at each stage of their journey.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70062","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T01:20:59Z","timestamp":1762737659000},"page":"185-194","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Shared Decision\u2010Making in Treatment Selection in Multiple Myeloma in Spain: The\n                    <scp>PRISMMA<\/scp>\n                    Study"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6248-2549","authenticated-orcid":false,"given":"Valent\u00edn","family":"Caba\u00f1as","sequence":"first","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Virgen de la Arrixaca  Murcia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-7688","authenticated-orcid":false,"given":"Mar\u00eda","family":"Casanova","sequence":"additional","affiliation":[{"name":"Hospital Costa del Sol Marbella  Marbella Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Barrag\u00e1n","sequence":"additional","affiliation":[{"name":"Grupo Espa\u00f1ol de Pacientes con C\u00e1ncer (GEPAC)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Grupo Espa\u00f1ol de Pacientes con C\u00e1ncer (GEPAC)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Raya","sequence":"additional","affiliation":[{"name":"AMGEN S.A.  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8100-4903","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Santiago\u2010Josefat","sequence":"additional","affiliation":[{"name":"AMGEN S.A.  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00165-X"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02541-1"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2018.01.015"},{"key":"e_1_2_13_6_1","volume-title":"StatPearls [Internet]","author":"Ahmed A.","year":"2025"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.06.013"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0020"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390202"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2077-6"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibac099"},{"key":"e_1_2_13_13_1","unstructured":"Spanish Society of Hematology and Hemotherapy Get to Know Us [updated as in 4th of April 2024] [Internet] 2024 https:\/\/www.sehh.es\/conocenos\/la\u2010sehh\u2010fehh."},{"key":"e_1_2_13_14_1","volume-title":"Sampling Techniques","author":"Cochran W. G.","year":"1977"},{"key":"e_1_2_13_15_1","unstructured":"Spanish Network of Cancer Registries [REDECAN] Cancer Prevalence in Spain as of 12\u201031\u20102020 [Internet] 2021 https:\/\/redecan.org\/en\/projects\/10\/cancer\u2010prevalence\u2010in\u2010spain\u2010as\u2010of\u201012\u201031\u20102020."},{"key":"e_1_2_13_16_1","unstructured":"Ranking Europeo: \u00bfEn Qu\u00e9 Especialidades Tiene M\u00e1s M\u00e9dicos Espa\u00f1a? Redacci\u00f3n M\u00e9dica [Internet]. 2017 Oct 12 [cited 2025 Mar 26] https:\/\/www.redaccionmedica.com\/secciones\/medicina\/ranking\u2010europeo\u2010en\u2010que\u2010especialidades\u2010tiene\u2010mas\u2010medicos\u2010espana\u2010\u20109749."},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191940"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.6696"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.239"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hex.12515"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2019.04.028"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.zefq.2024.04.002"},{"issue":"7","key":"e_1_2_13_23_1","first-page":"305","article-title":"PARTNER\u2010Project\u2009: A Model and Tools to Support Shared Decision Making in Relapsed\/Refractory Multiple Myeloma (RRMM) Treatment","volume":"12","author":"Sillis L.","year":"2021","journal-title":"Belgian Journal of Hematology"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5467-x"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.686165"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12589-9"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S474722"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-021-00501-7"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724"},{"key":"e_1_2_13_31_1","unstructured":"Spanish Ministry of Health Cancer Strategy of the Spanish National Health System. Update Approved by the National Health System Interterritorial Council on February 24 2021 [Internet] 2024 https:\/\/www.sanidad.gob.es\/areas\/calidadAsistencial\/estrategias\/cancer\/docs\/Accesibilidad_Cancer_Strategy_SNHS_OK._ACCESIBLE.pdf."}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:10:20Z","timestamp":1767874220000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ejh.70062"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70062","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]},"assertion":[{"value":"2025-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}